Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234740 · ClinicalTrials.gov registry record · Phase 1
Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases
A Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 2
- Study locations
NCT01234740: Completed Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, sponsored by City of Hope Medical Center.
NCT01234740 is a Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma that has completed, run by City of Hope Medical Center. The registered enrollment target is 7 participants, below the 43-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01234740, a Phase 1 study of Adult Glioblastoma and Adult Giant Cell Glioblastoma, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 2
- Study locations
Study Summary
RATIONALE: Bafetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial studies bafetinib in treating patients with recurrent high-grade glioma or brain metastases.
Conditions Studied
Interventions
- OTHER pharmacological study
- OTHER mass spectrometry
- DRUG bafetinib
- PROCEDURE microdialysis
- OTHER liquid chromatography
Study Locations (2)
California
- City of Hope Medical Center - Duarte
- South Pasadena Cancer Center - South Pasadena
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
What the finished NCT01234740 record still lists
NCT01234740 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 43-participant average among 14 other Adult Glioblastoma trials with a reported enrollment target (84% lower).
The record links to 10 conditions, with Adult Glioblastoma appearing as the primary indexed condition, and to 5 interventions - of which pharmacological study is the first listed.
NCT01234740 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01234740 about?
NCT01234740 is a clinical study titled "Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases". RATIONALE: Bafetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial studies bafetinib in treating patients with recurrent high-grade glioma or brain metastases.
What is the current status of trial NCT01234740?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2010-12. Estimated completion is 2013-03.
What conditions does trial NCT01234740 study?
This clinical trial studies the following conditions: Adult Glioblastoma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor, Adult Anaplastic Astrocytoma.
What interventions are being tested in trial NCT01234740?
The interventions under investigation include: pharmacological study (OTHER), mass spectrometry (OTHER), bafetinib (DRUG), microdialysis (PROCEDURE), liquid chromatography (OTHER).
Who is sponsoring clinical trial NCT01234740?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01234740 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adult Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01234740's enrollment target sits among peer trials
7 15th of 14 the lowest of 14 other Adult Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adult Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
ACTIVE NOT RECRUITING · Phase 1
-
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
ACTIVE NOT RECRUITING · Phase 1
-
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
COMPLETED · Phase 1
-
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
COMPLETED · Phase 1
-
Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia